Dotor De Las Herrerias; Javier

Patent Applications and Registrations

Patent applications and USPTO patent grants for Dotor De Las Herrerias; Javier.The latest application filed is for "use of transforming growth factor - beta 1 (tgf-b1) inhibitor peptides for the treatment of corneal fibrosis and/or haze".

Company Profile

0.6.4

Dotor De Las Herrerias; Javier - Madrid ES
Dotor De Las Herrerias; Javier - Cizur Mayor ES
Dotor De Las Herrerias; Javier - Pamplona - Navarra ES
Dotor De Las Herrerias; Javier - Navarra ES
Dotor De Las Herrerias; Javier - Pamplona ES

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Method for predicting and monitoring clinical response to immunomodulatory therapy Grant 11,175,282 - Dotor De Las Herrerias , et al. November 16, 2	2021-11-16
Peptide for the prophylactic or therapeutic treatment of skin tumors in initial stages Grant 8,658,599 - Insa Boronat , et al. February 25, 2	2014-02-25
Use Of Transforming Growth Factor - Beta 1 (tgf-b1) Inhibitor Peptides For The Treatment Of Corneal Fibrosis And/or Haze App 20120315256 - Dotor De Las Herrerias; Javier ; et al.	2012-12-13
Peptides with capacity for binding with interleukine 10 (IL-10) Grant 8,148,334 - Manterola Careaga , et al. April 3, 2	2012-04-03
Peptide for the Prophylactic or Therapeutic Treatment of Skin Tumors in Initial Stages App 20120065144 - Insa Boronat; Raul ; et al.	2012-03-15
Peptides With Capacity For Binding With Interleukine 10 (il-10) App 20100168015 - Manterola Careaga; Lorea ; et al.	2010-07-01
Peptides with the capacity to bind to transforming growth factor .beta.1 (TGF-.beta.1) Grant 7,666,841 - Dotor De Las Herrerias , et al. February 23, 2	2010-02-23
Use Of Tgf-b1 Inhibitor Peptides In The Preparation Of An Immune Response Modulating Agent App 20090263410 - Borras Cuesta; Francisco ; et al.	2009-10-22
Method for the treatment of skin fibrosis and suitable compositions for such treatment Grant 7,582,609 - Borras Cuesta , et al. September 1, 2	2009-09-01

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.